IA-66-41
|
Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.
| |
IA-66-66
|
APIs That Appear To Be Misbranded Under 502(f)(1) Because They Do Not Meet The Requirements For The Labeling Exemptions In 21 CFR
201.122
|
Human Medications, Human Drugs, Animal Medications, Animal Drugs, Pharmacy law, Pharmaceutical law, Compounding law, Sterile and Non Sterile Compounding 797 Compliance, Veterinary law, Veterinary Compounding Law; Health Care; Awareness of all Types of Compounding Issues; Pharmacy Benefit Managers (PBMs), Outsourcing Facilities Food and Drug Administration and Compliance Issues
Monday, July 7, 2014
Updated Import Alerts from FDA--Detention without Physical Examination of Unapproved New Drugs Promoted in the US and API that Appears to be Misbranded
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment